Chris Garabedian is the Chairman and CEO of Xontogeny, a venture studio he founded in 2016 to advance technologies from. See sector focus and contact routes.
Chris Garabedian is the Chairman and CEO of Xontogeny, a venture studio he founded in 2016 to advance technologies from early development through clinical proof of concept. He also serves as Portfolio Manager of the Perceptive Xontogeny Ventures Fund, which targets early-stage life science companies with Series A investments across biotech, medtech, and healthtech. His typical check size ranges between $100,000 and $10 million, with a focus on leading or supporting Series A rounds in biotechnology and pharmaceuticals. Notable portfolio companies include VivoSense, which raised $25 million in 2022, and Zucara Therapeutics, which secured $20 million in 2024. Garabedian emphasizes the venture studio model, arguing it provides startups not just capital but also an extended management team and network access. With decades of experience as a biopharma executive, including a prior role as President and CEO of Sarepta Therapeutics, he brings operational depth to his investment approach.
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in Boston.
Investors like Chris Garabedian · Full investor directory · Investor access · Company funding database